Given that 30%–40% of patients with KRAS-mutated lung cancer have co-existing TP53 mutations and poor prognoses, we evaluated the effect of WEE1 downregulation in KRAS-mutated NSCLC cell lines with or without TP53 mutations. This evidence concerns the gene TP53 and non-small cell lung carcinoma.